Crossmark

A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination

Crossref DOI link: https://doi.org/10.1038/s41591-021-01636-8

Published Online: 2022-02-03

Published Print: 2022-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Andrews, Sarah F. https://orcid.org/0000-0002-2583-1949
Raab, Julie E.

Gorman, Jason https://orcid.org/0000-0002-3775-6560
Gillespie, Rebecca A. https://orcid.org/0000-0001-5741-3699
Cheung, Crystal S. F.

Rawi, Reda

Cominsky, Lauren Y.

Boyington, Jeffrey C.

Creanga, Adrian https://orcid.org/0000-0002-3087-8397
Shen, Chen-Hsiang

Harris, Darcy R.

Olia, Adam S.

Nazzari, Alexandra F.

Zhou, Tongqing https://orcid.org/0000-0002-3935-4637
Houser, Katherine V. https://orcid.org/0000-0002-2147-186X
Chen, Grace L.

Mascola, John R.

Graham, Barney S.

Kanekiyo, Masaru https://orcid.org/0000-0001-5767-1532
Ledgerwood, Julie E.

Kwong, Peter D. https://orcid.org/0000-0003-3560-232X
McDermott, Adrian B. https://orcid.org/0000-0003-0616-9117
Funding

Funding for this research was provided by:

Division of Intramural Research, National Institute of Allergy and Infectious Diseases

Simons Foundation (SF349247)

Empire State Development’s Division of Science, Technology and Innovation
License Information

Text and Data Mining valid from 2022-02-01

Version of Record valid from 2022-02-01
More Information

Article History

Received: 22 April 2021

Accepted: 19 November 2021

First Online: 3 February 2022

Competing interests

: J.C.B., B.S.G., J.R.M., M.K. and P.D.K. are named inventors of US patents 9,441,019, 10,137,190 and 10,363,301 on influenza hemagglutinin nanoparticle vaccines and stabilized hemagglutinin stem trimers and of several pending applications on related technologies filed by the Department of Health and Human Services (National Institutes of Health).

Document is current

Any future updates will be listed below